Antengene Corporation(06996.HK): ATG‑201 Receives HREC Approval in Australia for Phase I Clinical Trial
NewTimeSpace News: On August 25, 2026, Antengene Corporation(06996.HK) announced that the Phase I ATTRACT study of its in‑house developed ATG‑201, a CD19/CD3 bispecific T‑cell engager antibody for the treatment of B‑cell‑related autoimmune diseases, has been approved by Australia’s Human Research Ethics Committee. The Company has also completed the procedure for submitting the clinical trial notification to the Therapeutic Goods Administration.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
- Antengene Corporation(06996.HK): Plans Share Repurchase of Up to HK$50 Million
- Antengene Corporation Limited (06996.HK): Expected to Swing to Profit in Interim Period, Revenue to Hit RMB 490 Million to RMB 536 Million
- Antengene-B(06996.HK): Exclusive License Agreement Secured for ATG-106 with Potential Milestone Payments up to Approximately USD960.5 Million
